炭疽(Anthrax):治療薬開発パイプライン動向(世界、2015年上半期版)

◆英語タイトル:Anthrax - Pipeline Review, H1 2015
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GMDHC6142IDB
◆発行日:2015年1月30日
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆ページ数:161
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥224,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥448,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥672,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[炭疽(Anthrax):治療薬開発パイプライン動向(世界、2015年上半期版)]についてメールでお問い合わせはこちら
当調査レポートでは、世界における炭疽(Anthrax)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・炭疽(Anthrax)の概要
・炭疽(Anthrax)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・炭疽(Anthrax)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・炭疽(Anthrax)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・炭疽(Anthrax)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
*** レポート概要(サマリー)***

Anthrax – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Anthrax – Pipeline Review, H1 2015’, provides an overview of the Anthrax’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anthrax, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anthrax and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anthrax
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Anthrax and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Anthrax products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anthrax pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anthrax
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anthrax pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Anthrax Overview 9
Therapeutics Development 10
Pipeline Products for Anthrax – Overview 10
Pipeline Products for Anthrax – Comparative Analysis 11
Anthrax – Therapeutics under Development by Companies 12
Anthrax – Therapeutics under Investigation by Universities/Institutes 16
Anthrax – Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Anthrax – Products under Development by Companies 20
Anthrax – Products under Investigation by Universities/Institutes 23
Anthrax – Companies Involved in Therapeutics Development 24
Aduro BioTech, Inc. 24
Aradigm Corporation 25
Bavarian Nordic A/S 26
Bristol-Myers Squibb Company 27
ContraFect Corporation 28
Dynavax Technologies Corporation 29
Elusys Therapeutics, Inc. 30
Emergent BioSolutions Inc. 31
Evolva SA 32
Green Cross Corporation 33
Grifols, S.A. 34
Hawaii Biotech, Inc. 35
iBio, Inc. 36
Immunovaccine, Inc. 37
Innovative Biologics, Inc. 38
Microbiotix, Inc. 39
NanoBio Corporation 40
Navigen Pharmaceuticals, Inc. 41
Oragenics, Inc. 42
PaxVax 43
Pfenex Inc. 44
Planet Biotechnology Inc. 45
Protein Potential, LLC 46
ProThera Biologics, LLC. 47
PsiOxus Therapeutics, Ltd. 48
Revivicor, Inc. 49
SelectX Pharmaceuticals, Inc. 50
Soligenix, Inc. 51
Summit Corporation plc 52
Syntiron LLC 53
Tetraphase Pharmaceuticals Inc. 54
The Medicines Company 55
Vaxin, Inc. 56
Anthrax – Therapeutics Assessment 57
Assessment by Monotherapy Products 57
Assessment by Combination Products 58
Assessment by Target 59
Assessment by Mechanism of Action 61
Assessment by Route of Administration 63
Assessment by Molecule Type 65
Drug Profiles 67
anthrax + plague vaccine – Drug Profile 67
anthrax vaccine – Drug Profile 68
anthrax vaccine – Drug Profile 70
anthrax vaccine – Drug Profile 71
anthrax vaccine – Drug Profile 72
anthrax vaccine – Drug Profile 73
anthrax vaccine – Drug Profile 74
anthrax vaccine – Drug Profile 75
anthrax vaccine – Drug Profile 76
anthrax vaccine – Drug Profile 78
anthrax vaccine – Drug Profile 80
anthrax vaccine next generation – Drug Profile 81
ARD-3100 – Drug Profile 82
AV-7909 – Drug Profile 84
CF-307 – Drug Profile 85
CF-308 – Drug Profile 86
ciprofloxacin hydrochloride – Drug Profile 87
DPX-Anthrax – Drug Profile 88
DV-230 – Drug Profile 89
EV-021 – Drug Profile 90
GC-1109 – Drug Profile 91
GREANX – Drug Profile 92
Human Antibody Based Vaccines – Drug Profile 93
KKL-35 – Drug Profile 95
MDX-1303 – Drug Profile 96
Monoclonal Antibody for Respiratory Anthrax – Drug Profile 98
Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax – Drug Profile 99
MU-1140 – Drug Profile 100
MVA-BN Anthrax – Drug Profile 102
NP-015 – Drug Profile 103
obiltoxaximab – Drug Profile 104
oritavancin diphosphate – Drug Profile 106
PBI-220 – Drug Profile 109
PreviThrax – Drug Profile 111
Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis – Drug Profile 113
Px-563L – Drug Profile 114
RiVax + VeloThrax – Drug Profile 115
Second Generation Px-563L – Drug Profile 116
SGX-204 – Drug Profile 117
Slit2N – Drug Profile 118
Small Molecule to Inhibit Anthrax Toxin for Anthrax – Drug Profile 120
Small Molecules for Bacterial Infections – Drug Profile 121
Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax – Drug Profile 122
Small Molecules to Inhibit Lethal Factor for Anthrax – Drug Profile 123
Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis – Drug Profile 125
Small Molecules to Inhibit MMP – Drug Profile 126
SMT-15000 – Drug Profile 127
TP-271 – Drug Profile 128
Anthrax – Recent Pipeline Updates 130
Anthrax – Dormant Projects 143
Anthrax – Discontinued Products 146
Anthrax – Product Development Milestones 147
Featured News & Press Releases 147
Appendix 157
Methodology 157
Coverage 157
Secondary Research 157
Primary Research 157
Expert Panel Validation 157
Contact Us 157
Disclaimer 158

[List of Tables]
Number of Products under Development for Anthrax, H1 2015 13
Number of Products under Development for Anthrax - Comparative Analysis, H1 2015 14
Number of Products under Development by Companies, H1 2015 16
Number of Products under Development by Companies, H1 2015 (Contd..1) 17
Number of Products under Development by Companies, H1 2015 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2015 19
Comparative Analysis by Late Stage Development, H1 2015 20
Comparative Analysis by Clinical Stage Development, H1 2015 21
Comparative Analysis by Early Stage Development, H1 2015 22
Products under Development by Companies, H1 2015 23
Products under Development by Companies, H1 2015 (Contd..1) 24
Products under Development by Companies, H1 2015 (Contd..2) 25
Products under Investigation by Universities/Institutes, H1 2015 26
Anthrax - Pipeline by Aduro BioTech, Inc., H1 2015 27
Anthrax - Pipeline by Aradigm Corporation, H1 2015 28
Anthrax - Pipeline by Bavarian Nordic A/S, H1 2015 29
Anthrax - Pipeline by Bristol-Myers Squibb Company, H1 2015 30
Anthrax - Pipeline by ContraFect Corporation, H1 2015 31
Anthrax - Pipeline by Dynavax Technologies Corporation, H1 2015 32
Anthrax - Pipeline by Elusys Therapeutics, Inc., H1 2015 33
Anthrax - Pipeline by Emergent BioSolutions Inc., H1 2015 34
Anthrax - Pipeline by Evolva SA, H1 2015 35
Anthrax - Pipeline by Green Cross Corporation, H1 2015 36
Anthrax - Pipeline by Grifols, S.A., H1 2015 37
Anthrax - Pipeline by Hawaii Biotech, Inc., H1 2015 38
Anthrax - Pipeline by iBio, Inc., H1 2015 39
Anthrax - Pipeline by Immunovaccine, Inc., H1 2015 40
Anthrax - Pipeline by Innovative Biologics, Inc., H1 2015 41
Anthrax - Pipeline by Microbiotix, Inc., H1 2015 42
Anthrax - Pipeline by NanoBio Corporation, H1 2015 43
Anthrax - Pipeline by Navigen Pharmaceuticals, Inc., H1 2015 44
Anthrax - Pipeline by Oragenics, Inc., H1 2015 45
Anthrax - Pipeline by PaxVax, H1 2015 46
Anthrax - Pipeline by Pfenex Inc., H1 2015 47
Anthrax - Pipeline by Planet Biotechnology Inc., H1 2015 48
Anthrax - Pipeline by Protein Potential, LLC, H1 2015 49
Anthrax - Pipeline by ProThera Biologics, LLC., H1 2015 50
Anthrax - Pipeline by PsiOxus Therapeutics, Ltd., H1 2015 51
Anthrax - Pipeline by Revivicor, Inc., H1 2015 52
Anthrax - Pipeline by SelectX Pharmaceuticals, Inc., H1 2015 53
Anthrax - Pipeline by Soligenix, Inc., H1 2015 54
Anthrax - Pipeline by Summit Corporation plc, H1 2015 55
Anthrax - Pipeline by Syntiron LLC, H1 2015 56
Anthrax - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015 57
Anthrax - Pipeline by The Medicines Company, H1 2015 58
Anthrax - Pipeline by Vaxin, Inc., H1 2015 59
Assessment by Monotherapy Products, H1 2015 60
Assessment by Combination Products, H1 2015 61
Number of Products by Stage and Target, H1 2015 63
Number of Products by Stage and Mechanism of Action, H1 2015 65
Number of Products by Stage and Route of Administration, H1 2015 67
Number of Products by Stage and Molecule Type, H1 2015 69
Anthrax Therapeutics - Recent Pipeline Updates, H1 2015 133
Anthrax - Dormant Projects, H1 2015 146
Anthrax - Dormant Projects (Contd..1), H1 2015 147
Anthrax - Dormant Projects (Contd..2), H1 2015 148
Anthrax - Discontinued Products, H1 2015 149

[List of Figures]
Number of Products under Development for Anthrax, H1 2015 13
Number of Products under Development for Anthrax - Comparative Analysis, H1 2015 14
Number of Products under Development by Companies, H1 2015 15
Number of Products under Investigation by Universities/Institutes, H1 2015 19
Comparative Analysis by Late Stage Development, H1 2015 20
Comparative Analysis by Clinical Stage Development, H1 2015 21
Comparative Analysis by Early Stage Products, H1 2015 22
Assessment by Monotherapy Products, H1 2015 60
Number of Products by Top 10 Targets, H1 2015 62
Number of Products by Stage and Top 10 Targets, H1 2015 62
Number of Products by Top 10 Mechanism of Actions, H1 2015 64
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 64
Number of Products by Top 10 Routes of Administration, H1 2015 66
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 67
Number of Products by Top 10 Molecule Types, H1 2015 68
Number of Products by Stage and Top 10 Molecule Types, H1 2015 68

*** 掲載企業 ***

Aduro BioTech, Inc.
Aradigm Corporation
Bavarian Nordic A/S
Bristol-Myers Squibb Company
ContraFect Corporation
Dynavax Technologies Corporation
Elusys Therapeutics, Inc.
Emergent BioSolutions Inc.
Evolva SA
Green Cross Corporation
Grifols, S.A.
Hawaii Biotech, Inc.
iBio, Inc.
Immunovaccine, Inc.
Innovative Biologics, Inc.
Microbiotix, Inc.
NanoBio Corporation
Navigen Pharmaceuticals, Inc.
Oragenics, Inc.
PaxVax
Pfenex Inc.
Planet Biotechnology Inc.
Protein Potential, LLC
ProThera Biologics, LLC.
PsiOxus Therapeutics, Ltd.
Revivicor, Inc.
SelectX Pharmaceuticals, Inc.
Soligenix, Inc.
Summit Corporation plc
Syntiron LLC
Tetraphase Pharmaceuticals Inc.
The Medicines Company
Vaxin, Inc.

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GMDHC6142IDB )"炭疽(Anthrax):治療薬開発パイプライン動向(世界、2015年上半期版)" (英文:Anthrax - Pipeline Review, H1 2015)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。